La solution topique de minoxidil aide-t-elle à traiter l'alopécie androgénétique ?

Across several placebo-controlled trials, women applying topical minoxidil solution grew more non-vellus (visible, pigmented) hairs than women applying placebo, over periods of 24 to 48 weeks. The effect appears in trials using 1%, 2%, 3%, and 5% concentrations, and in different populations, including women in Europe and Japan. The size of the benefit over placebo varies between studies, and not every woman in the active-treatment groups reported visible improvement.

What the placebo-controlled trials actually measured

The most direct evidence comes from randomised, double-blind, placebo-controlled trials that counted hairs in a fixed area of scalp before and after treatment. In one 48-week trial of 381 women with female pattern hair loss, both 2% and 5% topical minoxidil solution produced significantly greater increases in non-vellus hair count than placebo, with the 5% solution also rated better by patients themselves on treatment benefit, though it came with more scalp irritation and unwanted facial hair (essai contrôlé, 2004). A 32-week European trial of 346 women found a mean increase of 33 hairs in the 2% minoxidil group versus 19 in the placebo group, a statistically significant difference (controlled trial, 1993). A trial in 280 Japanese women testing 1% topical minoxidil solution over 24 weeks found a mean hair-count increase of 8.15 versus 2.03 with placebo (essai contrôlé, 2007). An older trial comparing 2% and 3% minoxidil solutions followed subjects for a full year and found substantial increases in total hair counts in all treated groups, including a group that started on placebo and switched to active treatment after four months, with no serious side effects reported (essai contrôlé, 1987). None of these figures can be read as a promise for any individual — average hair counts moved in the same direction across women, but investigator and patient assessments in these trials did not always agree with each other, and a proportion of women in every active-treatment arm saw no meaningful change.

How the different strengths and forms compare

A trial comparing a once-daily 5% minoxidil foam with a twice-daily 2% solution in 113 women found the foam was non-inferior on hair count and hair width, with similar or slightly better outcomes and notably lower rates of itching and dandruff (essai contrôlé, 2011). Separately, a formulation study using a lipid-based ('cetosomal') delivery system measured how much minoxidil actually reached the scalp and hair follicles compared with a standard solution; in a small pilot of 12 men, the new formulation showed greater scalp retention and follicular targeting with less drug passing into the bloodstream, though this was not a trial of hair regrowth itself (essai contrôlé, 2026). None of this compares topical solution against other delivery routes in women specifically — for a look at how oral minoxidil stacks up against the topical form, what the research says about treating androgenetic alopecia in women covers that ground in more depth.

Does it work as well as the oral tablet?

A meta-analysis pooling four randomised trials with 279 participants compared oral minoxidil directly against topical minoxidil solution in androgenetic alopecia. It found no significant difference in hair density or hair diameter between the two forms. The oral form was associated with a higher rate of hypertrichosis (excess hair growth on the body or face), while rates of low blood pressure did not differ significantly between groups (examen systématique, 2025). A separate small trial looked at what happens when minoxidil is delivered into the scalp by microneedling rather than applied as a solution, and found measurable changes in blood pressure afterwards, evidence that the drug is absorbed into the body even when applied locally (essai contrôlé, 2025). Neither of these findings changes what the placebo-controlled trials above showed about the topical solution's own effect on hair growth; they speak to how it compares with other ways of getting minoxidil into the system.

What isn't in these abstracts

Les essais décrits ici qui testent spécifiquement la solution topique de minoxidil contre un placebo chez les femmes s'échelonnent de 1993 à 2011, avec des concentrations de 1 % à 5 %. Aucun des résumés ne rapporte l'utilisation à long terme au-delà d'un an, ce qui se passe aux comptes de cheveux après l'arrêt du traitement, ou comment les effets diffèrent selon l'âge dans la gamme 18-49 ans enregistrée. La méta-analyse de l'archive comparant les formes orales et topiques ne couvre que 24 à 39 semaines de suivi. Pour une vue plus large de la façon dont le minoxidil s'inscrit aux côtés d'autres approches, les méta-analyses sur les traitements de l'alopécie androgénétique et plus large archive des cheveux et des ongles rassemblent davantage de ce qui a été étudié, y compris les options basées sur la lumière et les injections non détaillées ici.

Ce qui reste encore inconnu

Les résumés conservés ici ne traitent pas de la façon dont la solution topique de minoxidil se compare directement aux nouvelles formulations topiques chez les femmes, et ils ne rapportent pas les résultats au-delà d'environ un an d'utilisation. Ils ne décrivent pas quelle proportion de repousse capillaire est conservée ou perdue après l'arrêt du traitement, et ils ne comparent pas la solution topique aux procédures d'injection du cuir chevelu ou à la luminothérapie directement dans le même essai. Lorsque ces questions sont importantes pour elle, les pages voisines sur les injections du cuir chevelu et la luminothérapie peuvent être une étape suivante plus directe.